pneumococcal 13-valent conjugate vaccine
Trade name: prevnar 13
Vaccineapproved
Approved
Feb 24, 2010
Pneumococcal conjugate vaccine is a pneumococcal vaccine made with the conjugate vaccine method and used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children. — Wikipedia
Clinical trial activity
336 trials · 166 clinical orgs · 1 marketing orgs
Phase 1
48
Phase 2
214
Phase 3
128
Phase 4
71
Earliest trial started Nov 1, 2000 (NCT00729001)
Timeline
Indications
Approved for
Studied for
- Aging · Early Phase 1
- Anemia, Sickle Cell · Phase 2
- Apnea · Phase 4
- Arthritis, Rheumatoid · Phase 4
- Asthma · Phase 4
- Ataxia Telangiectasia · Phase 3
- Autoimmune Diseases · Phase 4
- Axial Spondyloarthritis · Phase 4
- Bacterial Infections · Phase 3
- BCG Vaccine · Phase 4
- beta-Thalassemia · Phase 4
- Bone Marrow Transplantation · Phase 4
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Early Phase 1
- Chickenpox · Phase 3
- Cholangiocarcinoma · Early Phase 1
- Colorectal Neoplasms · Phase 1
- Common Variable Immunodeficiency · Phase 2
- Communicable Diseases · Phase 2
- Coronavirus · Phase 2
- Coronavirus Infections · Phase 4
- Cough · Phase 4
- COVID-19 · Phase 4
- Crohn Disease · Phase 4
- Dengue · Phase 3
- Dengue Virus · Phase 2
- Diphtheria · Phase 4
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 4
- Diphtheria Toxoid · Phase 3
- Drug Therapy, Combination · Phase 4
- Encephalitis · Phase 3
- Esophageal and Gastric Varices · Phase 2
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Febrile Neutropenia · Phase 4
- Fever · Phase 4
- Haemophilus Infections · Phase 3
- Haemophilus influenzae · Phase 4
- Haemophilus influenzae type b · Phase 3
- Hamartoma · Phase 1/Phase 2
- Healthy Volunteers · Phase 4
- Hematopoietic Stem Cell Transplantation · Phase 3
- Hepatitis A · Phase 4
- Hepatitis A virus · Phase 4
- Hepatitis B · Phase 3
- Herpes Zoster · Phase 3
- HIV · Phase 4
- HIV Infections · Phase 4
- Hypoxia · Phase 3
- IgG Deficiency · Phase 2
- Immune System Diseases · Phase 4
- Immune Tolerance · Phase 2
- Immunity · Phase 4
- Immunization · Phase 4
- Infant · Phase 4
- Infant, Premature, Diseases · Phase 4
- Inflammatory Bowel Diseases · Phase 2
- Influenza, Human · Phase 4
- Intestinal Neoplasms · Phase 1/Phase 2
- Kidney Failure, Chronic · Phase 4
- Kidney Transplantation · Phase 4
- Leukemia · Phase 2
- Leukemia, B-Cell · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 4
- Liver Transplantation · Phase 4
- Lupus Erythematosus, Systemic · Phase 4
- Lymphoma · Phase 4
- Lymphoma, B-Cell · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 2
- Malaria · Phase 2
- Measles · Phase 3
- Measles-Mumps-Rubella Vaccine · Phase 3
- Meningitis · Phase 4
- Meningitis, Meningococcal · Phase 4
- Meningococcal Infections · Phase 4
- Meningococcal Vaccines · Phase 3
- Multiple Myeloma · Phase 4
- Multiple Sclerosis · Phase 2
- Mumps · Phase 3
- Mumps Vaccine · Phase 2
- Neisseria meningitidis · Phase 3
- Neoplasms · Phase 2
- Neoplasms, Plasma Cell · Phase 4
- Otitis Media · Phase 4
- Otitis Media with Effusion · Phase 4
- Ovarian Neoplasms · Phase 1/Phase 2
- Pain · Phase 4
- Pertussis Vaccine · Phase 4
- Pneumococcal Infections · Phase 4
- Pneumococcal Vaccines · Phase 4
- Pneumonia · Phase 4
- Pneumonia, Bacterial · Phase 2
- Pneumonia, Pneumococcal · Phase 4
- Pneumonia, Staphylococcal · Phase 4
- Poliomyelitis · Phase 4
- Poliovirus Vaccines · Phase 3
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 4
- Premature Birth · Phase 3
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Renal Insufficiency, Chronic · Phase 4
- Respiratory Tract Infections · Phase 4
- Rotavirus Infections · Phase 3
- Rotavirus Vaccines · Phase 3
- Rubella · Phase 3
- Rubella Vaccine · Phase 2
- Salmonella Infections · Phase 2
- SARS-CoV-2 · Phase 2
- Seizures, Febrile · Phase 4
- Sepsis · Phase 4
- Severe Acute Malnutrition · Phase 4
- Severe Acute Respiratory Syndrome · Phase 2
- Severe Dengue · Phase 3
- Sjogren's Syndrome · Phase 4
- Spleen · Phase 4
- Splenectomy · Phase 2
- Spondylarthropathies · Phase 4
- Streptococcal Infections · Phase 3
- Streptococcus pneumoniae · Phase 4
- Systemic Vasculitis · Phase 4
- Tetanus · Phase 4
- Thalassemia · Phase 4
- Transplants · Phase 4
- Tuberculosis · Phase 2
- Typhoid Fever · Phase 2
- Urinary Bladder Neoplasms · Phase 1
- Vaccination · Phase 4
- Vaccines · Phase 4
- Virus Diseases · Phase 3
- Whooping Cough · Phase 4
- Yellow Fever · Phase 3
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Approval history
- approvedFeb 24, 2010
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPneumococcal conjugate vaccine ↗
Also known as
- 13-valent pneumococcal vaccine
- bk-um peptide
- corynebacterium diphtheriae crm197 protein
- crm197
- crm197
- crm 197
- crm-197
- crm-197
- crm197 (non-toxic variant of diphtheria toxin)
- crm(197) of diphtheria toxin
- cross reacting material 197
- cross reacting material (crm(197)) of diphtheria toxin
- diptheria crm197 protein
- diptheria toxin mutant crm19
- nbp606
- pcv13
- pcv-13
- pcv13a
- pcv13a vaccine
- pcv-13 vaccine
- pcv13 vaccine
- pneumo-bacterin
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)
- pneumococcal 7-valent conjugate vaccine (diphtheria crm197 protein)
- pneumococcal polysaccharide serotype 1 /pneumococcal polysaccharide serotype 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f, 23f /pneumococcal polysaccharide serotype 14 /pneumococcal polysaccharide serotype 18c /pneumococcal polysaccharide serotype 19f / pneumococcal polysaccharide serotype 23f /pneumococcal polysaccharide serotype 4 /pneumococcal polysaccharide serotype 5 /pneumococcal polysaccharide serotype 6b /pneumococcal polysaccharide serotype 7f /pneumococcal polysaccharide serotype 9v
- pneumococcal polysaccharide serotype 1 /pneumococcal polysaccharide serotype 14 /pneumococcal polysaccharide serotype 18c /pneumococcal polysaccharide serotype 19a / pneumococcal polysaccharide serotype 19f /pneumococcal polysaccharide serotype 23f /pneumococcal polysaccharide serotype 3 /pneumococcal polysaccharide serotype 4 / pneumococcal polysaccharide serotype 5 / pneumococcal polysaccharide serotype 6a / pneumococcal polysaccharide serotype 6b /pneumococcal polysaccharide serotype 7f /pneumococcal polysaccharide serotype 9v protein
- pneumococcal polysaccharide serotype 4 /pneumococcal polysaccharide serotype 6b /pneumococcal polysaccharide serotype 9v /pneumococcal polysaccharide serotype 14 / pneumococcal oligosaccharide serotype 18c /pneumococcal polysaccharide serotype 19f /pneumococcal polysaccharide serotype 23f
- pneumococcal vaccine
- pneumococcal vaccine
- prevenar
- prevenar13
- prevenar13
- prevenar 13
- prevenar 13
- prevnar
- prevnar
- prevnar13
- prevnar 13
- prevnar 13
- prevnar 13
- primeboost conjugated anti- pneumococcal vaccine
- vi-crm197
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07252791 | Phase 4 | Jan 1, 2026 | Insituto Adolfo Lutz, University of Sao Paulo |
| NCT07242092 | Phase 4 | Jan 1, 2026 | Insituto Adolfo Lutz, University of Sao Paulo |
| NCT07135453 | Phase 4 | Dec 31, 2025 | Merck, University of Alabama, Birmingham |
| NCT07286370 | Phase 2 | Dec 17, 2025 | GlaxoSmithKline |
| NCT07284654 | Phase 3 | Dec 1, 2025 | Vaxcyte, Inc. |
| NCT07205289 | Phase 1 | Oct 31, 2025 | GPN Vaccines |
| NCT07017777 | Phase 3 | Oct 15, 2025 | Tianjin Cansino Biotechnology Inc |
| NCT07019909 | Phase 1 | Jul 6, 2025 | Pfizer |
| NCT06986239 | Phase 1 | Jul 1, 2025 | LiteVax BV |
| NCT07023081 | Phase 1 | Jun 15, 2025 | Pfizer |
| NCT06970756 | Phase 1 | May 27, 2025 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT06817421 | Phase 4 | Apr 30, 2025 | Menzies School of Health Research, Murdoch University, University of Edinburgh, University of Western Australia |
| NCT06855160 | Phase 3 | Apr 17, 2025 | GlaxoSmithKline |
| NCT06806137 | Phase 3 | Mar 5, 2025 | GlaxoSmithKline |
| NCT06740630 | Phase 3 | Dec 17, 2024 | GlaxoSmithKline |
| NCT06693895 | Phase 3 | Nov 19, 2024 | GlaxoSmithKline |
| NCT06647407 | Phase 1/Phase 2 (Phase 2) | Oct 28, 2024 | Sanofi-Aventis |
| NCT06617715 | Phase 3 | Oct 12, 2024 | China National Pharmaceutical Group, Government of China |
| NCT06550830 | Phase 1 | Aug 28, 2024 | China National Pharmaceutical Group, Government of China |
| NCT06703203 | Phase 1/Phase 2 (Phase 2) | Aug 27, 2024 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
Showing 20 of 336 trials
Page 1 / 17
Organizations
Research & Development (166)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 57 | 55 | 3 | 2000 |
| Sanofi | For profit | 38 | 36 | 4 | 2002 |
| Pfizer | For profit | 37 | 30 | 5 | 2002 |
| Merck | For profit | 31 | 27 | 4 | 2006 |
| Sanofi-Aventis | For profit | 27 | 16 | 4 | 2007 |
| Novartis | For profit | 15 | 14 | 4 | 2004 |
| University of London | Academic/Hospital | 9 | 3 | 3 | 2006 |
| Government of China | Government | 7 | 1 | 2 | 2020 |
| University of Paris | Academic/Hospital | 7 | 5 | 2 | 2008 |
| Wyeth | For profit | 7 | 0 | 3 | 2002 |
| National Cancer Institute (NCI) | Government | 6 | 1 | 3 | 2011 |
| Murdoch University | Academic/Hospital | 5 | 0 | 2 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 2 | 2 | 2005 |
| University of Oxford | Academic/Hospital | 5 | 5 | 3 | 2008 |
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 4 | 4 | 4 | 2020 |
| Korea University | Academic/Hospital | 4 | 4 | 1 | 2012 |
| Mayo Clinic | Academic/Hospital | 4 | 4 | 3 | 2015 |
| Menzies School of Health Research | Academic/Hospital | 4 | 4 | 2 | 2011 |
| PATH | Academic/Hospital | 4 | 2 | 2 | 2011 |
| Affinivax | For profit | 3 | 1 | 2 | 2019 |
166 organizations
Page 1 / 9